{"entity":{"id":"paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025","kind":"paper","name":"SQ3370 phase 1/2a results in advanced solid tumours and soft tissue sarcoma (preprint)","aka":["A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors"],"tldr":"The full clinical results of the only trial of SQ3370, posted before peer review. The treatment was well tolerated at very high doses, but 2 of 14 sarcoma patients responded, about what ordinary doxorubicin achieves, and the trial was stopped.","summary":"A preprint, posted on medRxiv on 3 June 2025 and not peer reviewed when read, reporting both parts of NCT04106492. Treatment was an injection of the biopolymer SQL70 into a tumour followed by three or five consecutive daily infusions of the doxorubicin prodrug SQP33. The primary endpoints were treatment-emergent adverse events, dose-limiting toxicities and the recommended phase 2 dose; pharmacokinetics, efficacy and immune profiling were secondary.\n\nPhase 1 enrolled 39 patients. SQ3370 at 0.38 to 15 times the standard doxorubicin dose was well tolerated, with no dose-limiting toxicity reported and mild and manageable myelosuppression. Doxorubicin was released rapidly at every dose level, with exposure rising up to 15 times the standard dose, and 12 times was selected as the recommended phase 2 dose.\n\nPhase 2a enrolled 14 patients with soft tissue sarcoma at that dose. The unconfirmed objective response rate was 14.3 per cent (2 of 14) and the disease control rate 71.4 per cent (10 of 14; 95% CI 41.9 to 91.6). Immune profiling showed expansion and activation of cytotoxic CD8 T cells, and tumours shrank in non-injected as well as injected lesions. The study was terminated because the prespecified criterion for continuing, an objective response rate greater than that of standard doxorubicin, was not met.","asOf":"2026-11-16","links":[{"label":"medRxiv 2025 (preprint)","url":"https://doi.org/10.1101/2025.06.02.25328445"},{"label":"Europe PMC","url":"https://europepmc.org/article/PPR/PPR1030310"},{"label":"ClinicalTrials.gov NCT04106492","url":"https://clinicaltrials.gov/study/NCT04106492"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["click-activated-prodrugs"],"targets":[],"drugs":["sq3370"],"companies":["shasqi"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04106492"],"people":["sant-chawla"],"bottlenecks":[],"keyPapers":[],"journals":["medrxiv"],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo (company site, ClinicalTrials.gov v2, Crossref, Europe PMC, NIH RePORTER)","editedOn":"2026-11-16"},"journal":"medRxiv","year":2025,"doi":"10.1101/2025.06.02.25328445","authors":"Chawla SP, Abella E, Wieland S, et al.","paperType":"observational","findings":["Phase 1: 39 patients, 0.38 to 15 times the standard doxorubicin dose, no dose-limiting toxicities; 12 times the standard dose chosen as the recommended phase 2 dose.","Phase 2a: unconfirmed objective response rate 14.3 per cent (2 of 14 patients with soft tissue sarcoma).","Phase 2a: disease control rate 71.4 per cent (10 of 14; 95% CI 41.9 to 91.6).","The study was terminated because the prespecified criterion of a response rate greater than standard doxorubicin was not met."],"whatItMeans":"For a person with sarcoma, this is a treatment that was easier to tolerate than its dose would suggest but did not work better than doxorubicin in the small group tested, and it is not available. For the field, it is the human proof that click activation works as chemistry, which is why the company has moved to versions guided by tumour-binding proteins.","caveats":["A preprint: not peer reviewed when read on 16 November 2026. Figures are from its abstract.","Responses were unconfirmed, the phase 2a group was 14 people and there was no comparison arm; \"comparable to standard doxorubicin\" is the authors' comparison with historical figures.","Authors include Shasqi employees and the company sponsored the trial."],"changedPractice":false,"participants":53},"route":"/key-papers/paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"technology":[{"id":"click-activated-prodrugs","kind":"technology","name":"Click-activated prodrugs (bioorthogonal drug activation in the body)","route":"/technologies/click-activated-prodrugs/"}],"drug":[{"id":"sq3370","kind":"drug","name":"SQ3370","route":"/drugs/sq3370/"}],"company":[{"id":"shasqi","kind":"company","name":"Shasqi","route":"/companies/shasqi/"}],"trial":[{"id":"nct04106492","kind":"trial","name":"SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a)","route":"/trials/nct04106492/"}],"person":[{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/"}],"journal":[{"id":"medrxiv","kind":"journal","name":"medRxiv","route":"/journals/medrxiv/"}]}}